• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

以促血管生成的COL15A1 + 内皮细胞为特征的肺纤维化疾病和肺腺癌中肺血管的异位扩张。

Ectopic Expansion of Pulmonary Vasculature in Fibrotic Lung Disease and Lung Adenocarcinoma Marked by Proangiogenic COL15A1+ Endothelial Cells.

作者信息

Engelbrecht Eric, Kooistra Tristan, Burg Nathalie, Hariri Lida, Nguyen Trong, Brazee Patricia, Hla Timothy, Gochuico Bernadette R, Knipe Rachel S

机构信息

University of Louisville School of Medicine Louisville Kentucky USA.

Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA.

出版信息

Pulm Circ. 2025 Jun 3;15(2):e70102. doi: 10.1002/pul2.70102. eCollection 2025 Apr.

DOI:10.1002/pul2.70102
PMID:40463493
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12130637/
Abstract

Lung vasculature arises from both pulmonary and systemic (bronchial) circulations. Remodeling and structural changes in lung vasculature have been recognized in end-stage fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF) but have not been well characterized. The vasculature that expands and supplies lung cancers is better described, with the recent recognition that systemic bronchial circulation expands to be the main blood supply to primary lung tumors. Here, we use publicly available single-cell RNA-sequencing (scRNA-seq) data to compare vascular endothelial cell (EC) populations in multiple progressive interstitial lung diseases (ILD) and non-small cell lung cancer (NSCLC) to identify common and distinct features. Lung tissue specimens were collected from healthy lung tissue (= 59), ILD (= 97), chronic obstructive pulmonary disease (= 22), and NSCLC (= 8). We identify two subtypes of expanded EC populations in both ILD and NSCLC, "Bronch-1" and "Bronch-2", expressing transcripts associated with venules and angiogenic tip/stalk cells, respectively. Relative to pulmonary capillary and arterial ECs, bronchial ECs show low expression of transcripts associated with vascular barrier integrity. The pan-bronchial EC marker COL15A1 showed positive staining in lung parenchyma from patients with IPF, SSc-ILD, and NSCLC, whereas positive staining was limited to subpleural and peri-bronchial regions in non-fibrotic controls. In conclusion, expansion of a subset of ECs expressing markers of the bronchial circulation is one of the most pronounced changes in vascular cell composition across multiple ILDs and NSCLC. These data support additional studies to determine the role of the bronchial vasculature in ILD progression.

摘要

肺血管系统起源于肺循环和体循环(支气管循环)。终末期纤维化肺病如特发性肺纤维化(IPF)中肺血管系统的重塑和结构变化已得到认可,但尚未得到充分描述。对扩张并为肺癌供血的血管系统有了更好的描述,最近认识到体循环支气管循环扩张成为原发性肺肿瘤的主要血液供应。在这里,我们使用公开可用的单细胞RNA测序(scRNA-seq)数据来比较多种进行性间质性肺病(ILD)和非小细胞肺癌(NSCLC)中的血管内皮细胞(EC)群体,以识别共同和不同的特征。从健康肺组织(=59例)、ILD(=97例)、慢性阻塞性肺疾病(=22例)和NSCLC(=8例)中收集肺组织标本。我们在ILD和NSCLC中均鉴定出两种扩张的EC群体亚型,即“支气管-1”和“支气管-2”,分别表达与小静脉和血管生成顶端/柄细胞相关的转录本。相对于肺毛细血管和动脉EC,支气管EC显示出与血管屏障完整性相关转录本的低表达。泛支气管EC标志物COL15A1在IPF、系统性硬化症相关ILD和NSCLC患者的肺实质中呈阳性染色,而在非纤维化对照中阳性染色仅限于胸膜下和支气管周围区域。总之,表达支气管循环标志物的EC亚群的扩张是多种ILD和NSCLC中血管细胞组成最显著的变化之一。这些数据支持进一步研究以确定支气管血管系统在ILD进展中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/f23e36320216/PUL2-15-e70102-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/3753acac3a6b/PUL2-15-e70102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/cb13d54710b2/PUL2-15-e70102-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/bdb9fff1105e/PUL2-15-e70102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/08578c5628f8/PUL2-15-e70102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/f23e36320216/PUL2-15-e70102-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/3753acac3a6b/PUL2-15-e70102-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/cb13d54710b2/PUL2-15-e70102-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/bdb9fff1105e/PUL2-15-e70102-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/08578c5628f8/PUL2-15-e70102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8ddc/12130637/f23e36320216/PUL2-15-e70102-g005.jpg

相似文献

1
Ectopic Expansion of Pulmonary Vasculature in Fibrotic Lung Disease and Lung Adenocarcinoma Marked by Proangiogenic COL15A1+ Endothelial Cells.以促血管生成的COL15A1 + 内皮细胞为特征的肺纤维化疾病和肺腺癌中肺血管的异位扩张。
Pulm Circ. 2025 Jun 3;15(2):e70102. doi: 10.1002/pul2.70102. eCollection 2025 Apr.
2
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.尼达尼布:在纤维化间质性肺疾病中的研究进展。
Drugs. 2021 Apr;81(5):575-586. doi: 10.1007/s40265-021-01487-0. Epub 2021 Mar 25.
3
Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.特发性肺纤维化和系统性硬化症相关间质性肺疾病单细胞分析中的不同干扰素信号传导和共享异常基底样细胞
Front Immunol. 2021 Mar 30;12:595811. doi: 10.3389/fimmu.2021.595811. eCollection 2021.
4
Molecular Changes Implicate Angiogenesis and Arterial Remodeling in Systemic Sclerosis-Associated and Idiopathic Pulmonary Hypertension.分子变化提示血管生成和动脉重构在系统性硬化症相关和特发性肺动脉高压中的作用。
Arterioscler Thromb Vasc Biol. 2024 Aug;44(8):e210-e225. doi: 10.1161/ATVBAHA.123.320005. Epub 2024 Jun 6.
5
The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution.单细胞分辨率下的致死性 COVID-19 和特发性肺纤维化的肺血管系统。
Cardiovasc Res. 2023 Mar 31;119(2):520-535. doi: 10.1093/cvr/cvac139.
6
Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.美国非特发性肺纤维化纤维化性间质性肺疾病患者疾病进展的基于索赔的患病率。
Ann Am Thorac Soc. 2022 Jul;19(7):1112-1121. doi: 10.1513/AnnalsATS.202102-222OC.
7
Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality.气道巨噬细胞中胶原 1a1 的表达增加与纤维化 ILD 有关,并与 FVC 下降和死亡率增加相关。
Front Immunol. 2021 Nov 17;12:645548. doi: 10.3389/fimmu.2021.645548. eCollection 2021.
8
Monthly pulse methylprednisolone infusions in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases: a single-center retrospective analyses.非特发性肺纤维化间质性肺疾病患者每月静脉输注甲泼尼龙:一项单中心回顾性分析
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251342661. doi: 10.1177/17534666251342661. Epub 2025 May 30.
9
Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.系统性硬化症相关间质性肺病患者肺组织中表达内皮细胞和间充质细胞基因产物的内皮细胞。
Arthritis Rheumatol. 2016 Jan;68(1):210-7. doi: 10.1002/art.39421.
10
Immunological Features and Potential Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.系统性硬化症相关间质性肺疾病和特发性肺纤维化的免疫学特征及潜在生物标志物
Clin Respir J. 2025 Apr;19(4):e70072. doi: 10.1111/crj.70072.

本文引用的文献

1
Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis.空间转录组学鉴定出与肺纤维化中远端肺重塑相关的分子微环境失调。
Nat Genet. 2025 Mar;57(3):647-658. doi: 10.1038/s41588-025-02080-x. Epub 2025 Feb 3.
2
Vascular involvement in idiopathic pulmonary fibrosis.特发性肺纤维化中的血管受累情况。
ERJ Open Res. 2024 Nov 25;10(6). doi: 10.1183/23120541.00550-2024. eCollection 2024 Nov.
3
Efficacy and Safety of Admilparant, an LPA Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
LPA拮抗剂Admilparant在肺纤维化中的疗效与安全性:一项2期随机临床试验
Am J Respir Crit Care Med. 2025 Feb;211(2):230-238. doi: 10.1164/rccm.202405-0977OC.
4
Immune mechanisms in fibrotic interstitial lung disease.纤维化性间质性肺疾病中的免疫机制。
Cell. 2024 Jul 11;187(14):3506-3530. doi: 10.1016/j.cell.2024.05.015.
5
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.贝索特格拉斯特治疗特发性肺纤维化患者:INTEGRIS-IPF 临床试验。
Am J Respir Crit Care Med. 2024 Aug 15;210(4):424-434. doi: 10.1164/rccm.202403-0636OC.
6
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.帕姆单抗治疗特发性肺纤维化:ZEPHYRUS-1 随机临床试验。
JAMA. 2024 Aug 6;332(5):380-389. doi: 10.1001/jama.2024.8693.
7
Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis.STRIVE-IPF 试验设计——特发性肺纤维化急性加重症治疗性血浆置换、利妥昔单抗和静脉注射免疫球蛋白的研究。
BMC Pulm Med. 2024 Mar 20;24(1):143. doi: 10.1186/s12890-024-02957-3.
8
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.一种小分子TNIK抑制剂在临床前和临床模型中靶向纤维化。
Nat Biotechnol. 2025 Jan;43(1):63-75. doi: 10.1038/s41587-024-02143-0. Epub 2024 Mar 8.
9
Ex vivo tissue perturbations coupled to single-cell RNA-seq reveal multilineage cell circuit dynamics in human lung fibrogenesis.体外组织扰动与单细胞 RNA 测序相结合,揭示了人类肺纤维化形成中的多谱系细胞回路动力学。
Sci Transl Med. 2023 Dec 6;15(725):eadh0908. doi: 10.1126/scitranslmed.adh0908.
10
Emerging role of immune cells as drivers of pulmonary fibrosis.免疫细胞在肺纤维化中的新作用。
Pharmacol Ther. 2023 Dec;252:108562. doi: 10.1016/j.pharmthera.2023.108562. Epub 2023 Nov 10.